Nello Mainolfi, Chief Executive Officer at Kymera Therapeutics, Inc. (KYMR), sold 80,000 shares at $112.80 ($9.2M) on 2026-07-01, disclosed to the SEC on 2026-07-02.
Scheduled sale ($9.2M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $112.80 | 1,883 | $212K | 2.3% |
| 2 | $113.98 | 6,626 | $755K | 8.2% |
| 3 | $114.96 | 24,105 | $2.8M | 30.0% |
| 4 | $115.69 | 44,050 | $5.1M | 55.3% |
| 5 | $116.56 | 3,336 | $389K | 4.2% |
| Total | $115.29 avg | 80,000 |
| $9.2M |
| 100% |
| Filing → |
| KYMR | SELL | 2026-04-29 | $2.4M | — | Filing → |
| KYMR | SELL | 2026-02-25 | $2.7M | — | Filing → |
| KYMR | SELL | 2025-12-31 | $4.7M | — | Filing → |